PEGBIO CO-B(02565) intends to discount 10% for a total of 5.136 million shares issued for sale, raising approximately HK$296 million.

PEGBIO CO-B(02565) Announced on December 12, 2025 (after trading hours), the company entered into a placing agreement with joint placing agents. Pursuant to this agreement, the company has conditionally agreed to place a total of 5,136,000 placing shares to not less than six placees at a price of HK$58.41 per placing share through the joint placing agents on a best efforts basis. The placing shares will be issued by the company in accordance with the terms and conditions set out in the placing agreement. Assuming no change in the issued share capital of the company from the date of this announcement to the completion date, the total number of 5,136,000 placing shares represents approximately: (i) approximately 1.84% of the existing H shares and approximately 1.33% of the total issued shares as at the date of this announcement; and (ii) approximately 1.81% of the enlarged H shares issued after the completion of the placement and approximately 1.31% of the total issued shares. The placing price of HK$58.41 per placing share represents a 10% discount to the closing price of HK$64.90 per share of H shares on the Stock Exchange of Hong Kong on December 12, 2025 (the date of the placing agreement). Assuming full subscription of all placing shares, the estimated total proceeds and net proceeds (after deducting the relevant costs and expenses to be borne by the company) from the placement will be approximately HK$300 million and approximately HK$296 million, respectively. The breakdown of the use of proceeds is as follows: 1. Approximately 40% for the development of a new generation of intelligent research and data platform; 2. Approximately 28% for repayment of loans and strengthening the company's capital structure; 3. Approximately 12% for the continued development of PB-2301 and PB-2309; 4. Approximately 10% for the establishment of a subsidiary in Hong Kong and accelerating the overseas business expansion of the group; 5. Approximately 10% for general corporate purposes and working capital.